RecruitingNot ApplicableNCT06345963
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
Sponsor
The University of Texas Health Science Center, Houston
Enrollment
120 participants
Start Date
May 21, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Plain Language Summary
Simplified for easier understanding
This study uses a brain stimulation technique called TMS (transcranial magnetic stimulation) to try to improve brain connectivity and symptoms in people with schizophrenia. TMS delivers gentle magnetic pulses to the scalp to activate specific brain regions without surgery.
**You may be eligible if...**
- You are between 18 and 60 years old
- You have been diagnosed with schizophrenia or a related condition
- You are able to give informed consent
**You may NOT be eligible if...**
- You have a history of seizures
- You have an unstable or acute medical condition affecting the brain (such as a recent stroke, brain tumor, or serious head injury)
- You are taking more than 400 mg of clozapine per day
- You have a device in your body (such as a pacemaker or metal implant in the head) that is not compatible with TMS
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEactive H-coil delivered rTMS
Multiple trains of rTMS in a day, for multiple days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06345963
Related Trials
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT0710511122 locations
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
NCT063407891 location
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT070612888 locations
Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.
NCT050365901 location
French Source-monitoring Task
NCT042371551 location